The association between therapeutic outcomes and VEGF G-1154A and C-936T gene polymorphisms in patients with glomerulonephritis

Background: In this present study, we aimed to investigate the association between therapeutic outcomes and vascular endothelial growth factor (VEGF) G-1154A and C-936T gene polymorphisms in patients with glomerulonephritis. Methods: Thirty-eight patients with glomerulonephritis diagnosed by renal biopsy were included to the study. All patients had proteinuria at least 1 gram (g)/day in urine analysis. At the end of a yearly therapy, patients with proteinuria less than 0.5 g/day were accepted as in complete remission and they were termed as group 1. The patients with proteinuria over 0.5 g/day were accepted as in no remission and they were termed as group 2. Results: The mean age of patients in group 1 and group 2 was 35.88 +/- 13.80 years and 37.30 +/- 13.89 years, respectively. There were nine (50%) male and nine (50%) female patients in group 1. In group 2, seven (35%) male and 13 (65%) female patients were present. Although VEGF G-1154A (GG) gene polymorphism was found in 55% of group 2 patients, and 22.2% of group 1 patients, but the differences did not reach statistical significance. There were no statistical differences between groups in terms of other gene polymorphisms. Namely, we obtained no statistical differences between therapeutic outcomes and gene polymorphisms. Conclusions: There is a significant difference between groups in terms of VEGF G-1154A (GG) gene polymorphism, but the minority of the patient population has led to not to reach statistical significance. So, this gene polymorphism has to be investigated in larger studies.

Yazar Terzi, Hatice
Kayatas, Mansur
Korkmaz, Serdal
Yildiz, Gursel
Candan, Ferhan
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/3456
Tek Biçim Adres 10.3109/0886022X.2014.900407
Konu Başlıkları Gene polymorphism
glomerulonephritis
proteinuria
therapeutic outcomes
vascular endothelial growth factor
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı RENAL FAILURE
Dergi Cilt Bilgisi 36
Dergi Sayısı 6
Sayfalar 904 - 907
Yayın Yılı 2014
Eser Adı
[dc.title]
The association between therapeutic outcomes and VEGF G-1154A and C-936T gene polymorphisms in patients with glomerulonephritis
Yazar
[dc.contributor.author]
Terzi, Hatice
Yazar
[dc.contributor.author]
Kayatas, Mansur
Yazar
[dc.contributor.author]
Korkmaz, Serdal
Yazar
[dc.contributor.author]
Yildiz, Gursel
Yazar
[dc.contributor.author]
Candan, Ferhan
Yayın Yılı
[dc.date.issued]
2014
Yayıncı
[dc.publisher]
TAYLOR & FRANCIS LTD
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Background: In this present study, we aimed to investigate the association between therapeutic outcomes and vascular endothelial growth factor (VEGF) G-1154A and C-936T gene polymorphisms in patients with glomerulonephritis. Methods: Thirty-eight patients with glomerulonephritis diagnosed by renal biopsy were included to the study. All patients had proteinuria at least 1 gram (g)/day in urine analysis. At the end of a yearly therapy, patients with proteinuria less than 0.5 g/day were accepted as in complete remission and they were termed as group 1. The patients with proteinuria over 0.5 g/day were accepted as in no remission and they were termed as group 2. Results: The mean age of patients in group 1 and group 2 was 35.88 +/- 13.80 years and 37.30 +/- 13.89 years, respectively. There were nine (50%) male and nine (50%) female patients in group 1. In group 2, seven (35%) male and 13 (65%) female patients were present. Although VEGF G-1154A (GG) gene polymorphism was found in 55% of group 2 patients, and 22.2% of group 1 patients, but the differences did not reach statistical significance. There were no statistical differences between groups in terms of other gene polymorphisms. Namely, we obtained no statistical differences between therapeutic outcomes and gene polymorphisms. Conclusions: There is a significant difference between groups in terms of VEGF G-1154A (GG) gene polymorphism, but the minority of the patient population has led to not to reach statistical significance. So, this gene polymorphism has to be investigated in larger studies.
Açıklama
[dc.description]
WOS: 000337949800013
Açıklama
[dc.description]
PubMed: 24673399
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Gene polymorphism
Konu Başlıkları
[dc.subject]
glomerulonephritis
Konu Başlıkları
[dc.subject]
proteinuria
Konu Başlıkları
[dc.subject]
therapeutic outcomes
Konu Başlıkları
[dc.subject]
vascular endothelial growth factor
Haklar
[dc.rights]
info:eu-repo/semantics/openAccess
ISSN
[dc.identifier.issn]
0886-022X
ISSN
[dc.identifier.issn]
1525-6049
İlk Sayfa Sayısı
[dc.identifier.startpage]
904
Son Sayfa Sayısı
[dc.identifier.endpage]
907
Dergi Adı
[dc.relation.journal]
RENAL FAILURE
Dergi Sayısı
[dc.identifier.issue]
6
Dergi Cilt Bilgisi
[dc.identifier.volume]
36
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.3109/0886022X.2014.900407
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/3456
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
237
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
15 Temmuz 2024 02:25
Google Kontrol
Tıklayınız
patients statistical between polymorphism differences polymorphisms proteinuria G-1154A remission female accepted termed significance glomerulonephritis present therapeutic outcomes groups investigated Namely obtained studies larger Although Conclusions population patient minority difference significant Background respectively Methods included biopsy
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms